[Cite as http://purl.org/au-research/grants/nhmrc/GNT1135682]
Prof Shudong Wang
A/Pr Elgene Lim
A/Pr Robert Milne
Prof Wayne Tilley
Brief description We have identified and patented novel drug molecules targeting enzymes namely CDKs 4 and 6, that are important for survival of cancer cells. The drugs are highly selective and potent against CDK4/6, well absorbed orally, and have attracted much interest from a pharmaceutical company. Further detailed work is needed to characterize fully their anti-cancer effects and toxicity, thereby securing a major investment from our commercial partner for drug development for treating cancers.
Funding Amount $1,171,199.00
Funding Scheme Development Grants